
Two NHS drugs slows and could REVERSE devastating Alzheimer's, ‘exciting' study finds
Click to share on Facebook (Opens in new window)
TWO NHS drugs could be combined to treat, and even reverse, the most common form of dementia, scientists claim.
A pair of cancer drugs have been identified as a powerful duo that may tackle Alzheimer's disease, after scientists sifted through 1,300 approved medicines.
Sign up for Scottish Sun
newsletter
Sign up
1
Alzheimer's was reversed in mice
Credit: Alamy
The American team used cutting-edge computer tools to match the gene changes seen in Alzheimer's patients with medicines that reverse those effects.
They found that two cancer drugs, both already available on the NHS, reduced brain degeneration in mice with the disease, and even brought back their memory.
The study, from the University of California, San Francisco (UCSF), first looked at how Alzheimer's alters the activity of individual brain cells.
They then searched for existing drugs that trigger the opposite changes, with the aim of rewiring damaged neurons and brain cells called glia.
And when they tested the top two candidates, letrozole and irinotecan, in lab mice, the results were impressive.
One theory of how Alzheimer's comes about is that sticky proteins - like amyloid-beta - start clumping together in the brain years before symptoms appear.
These toxic clumps block communication between brain cells and trigger inflammation, eventually causing the cells to die.
Some scientists believe this buildup is the root cause of Alzheimer's, so clearing it could stop the disease in its tracks.
When combined, the cancer drugs not only halted brain cell damage but also undid toxic clumps of proteins, restored memory and reversed the disease's genetic footprint.
Prof Marina Sirota, senior author, said: 'We're excited that our computational approach led us to a potential combination therapy for Alzheimer's based on existing FDA-approved medications.'
Common painkiller used for back pain ups risk of dementia by 29%, scientists warn
She added: 'Alzheimer's disease comes with complex changes to the brain, which has made it tough to study and treat — but our tools opened up the possibility of tackling that complexity directly.'
The scientists then trawled through the anonymised medical records of 1.4million over-65s and found those already taking the cancer drugs were less likely to develop Alzheimer's.
Dr Yaqiao Li, the study's lead author, said: 'Thanks to all these existing data sources, we went from 1,300 drugs, to 86, to 10, to just five.
'In particular, the rich data collected by all the UC health centres pointed us straight to the most promising drugs. It's kind of like a mock clinical trial.'
Letrozole is typically used to treat breast cancer, while irinotecan is prescribed for colon and lung cancer. Both are already used in the UK.
'So exciting'
Prof Yadong Huang, co-senior author, said: 'Alzheimer's is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health.
'This makes it very challenging for drug development - which traditionally produces one drug for a single gene or protein that drives disease.'
He added: 'It's so exciting to see the validation of the computational data in a widely used Alzheimer's mouse model.'
The breakthrough, published in the journal Cell, could fast-track trials in humans.
Prof Sirota said: 'If completely independent data sources, such as single-cell expression data and clinical records, guide us to the same pathways and the same drugs and then resolve Alzheimer's in a genetic model then maybe we're onto something.'
She added: 'We're hopeful this can be swiftly translated into a real solution for millions of patients with Alzheimer's.'
Alzheimer's causes a relentless decline in cognition, learning, and memory.
But decades of research have only produced two FDA-approved drugs, neither of which can meaningfully slow the decline. In the UK, no disease-modifying drugs are currently approved or available.
Instead, the UK relies on symptom-managing drugs, such as Donepezil and Rivastigmine.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Reuters
an hour ago
- Reuters
US FDA investigates third death after treatment with Sarepta's gene therapy Elevidys
July 25 (Reuters) - The U.S. Food and Drug Administration said on Friday it was investigating the death of an eight-year-old boy who received Sarepta Therapeutics' (SRPT.O), opens new tab muscular disorder gene therapy Elevidys. The death occurred on June 7, the agency said.


Daily Mail
3 hours ago
- Daily Mail
Trans doctor 'tried to mislead' tribunal over phone notes on Sandie Peggie
A trans doctor was trying to 'mislead' the landmark Sandie Peggie tribunal, it has been told. Phone notes made by female-identifying Dr Beth Upton following a dispute with the nurse had been edited, it was claimed. Ms Peggie was suspended from work at Victoria Hospital, Kirkcaldy, after she objected to the trans medic using the female changing area on Christmas Eve 2023. The 51-year-old has since launched an employment tribunal against NHS Fife and Dr Beth Upton. Yesterday it heard that NHS Fife did not commission a forensic or in-person check of Dr Upton's phone in May 2025. The health board's security analyst 'did not have a technical answer' for discrepancies on dates on Google Notes made by Dr Upton, the hearing was told. And IT expert Jim Borwick agreed with the suggestion the trans doctor 'was trying to mislead' the tribunal. Mr Borwick, director of KJB Computer Forensics Consultancy, had been commissioned by Ms Peggie's representatives to compile a report in to the notes. Mr Borwick wrote, 'Dr Upton is silent on fact that Notes can be rearranged with relative ease', and that he was 'perplexed' and 'at a loss' as to how the discrepancies had occurred, and was told 'notes did not include patient care allegations Dr Upton made about Ms Peggie'. One note from December 18, 2023, logged: 'Working nights, won't make eye contact, won't acknowledge my presence, haven't had direct conversation but can feel the dismissal/hostility.' But the tribunal heard it was edited on December 26 at 1.21am. Mr Borwick told the hearing: 'In addition to text on that date, this had been added so it is not contemporaneous.' Jane Russell, KC, for NHS Fife and Dr Upton, asked: 'When you said Dr Upton is silent on fact that notes can be re-arranged, you're suggesting that Dr Upton is trying to mislead the tribunal?' The IT expert told her: 'I suppose that's my comment, yes.' Ms Russell asked Mr Borwick if he had been instructed to come up with an 'explanation that there were lies on the part of Dr Upton' and to 'undermine Dr Upton's account of patient care allegations'. But the witness told her he was not 'trying to undermine anything', and added: 'I was told to recover notes about patient care allegations; no reason was given, just to recover those notes.' Ms Russell said in one screenshot, 'the conundrum is that the edited date predates the created date', and asked the witness if 'the only explanation for discrepancy is that Dr Upton is lying about creation dates?'. He said he could not recreate this, and nor could NHS Fife's information security manager Peter Donaldson. The tribunal heard a note entitled 'weird incident 26.08.23' was timestamped showing it was created on October 26, 2023, according to Google. Mr Donaldson told the tribunal: 'I don't believe Dr Upton was trying to mislead us in any way. 'I completely agree this is how Google presents; on the face of it the October date is the earliest date. I don't dispute that. The notes supplementary to that are the same.'


The Sun
3 hours ago
- The Sun
NHS strike chaos threatens to spread as paramedics REJECT pay offer on first day of doctors' walkout
NHS strikes threatened to spread yesterday as paramedics in the GMB union voted to reject their annual pay offer. It came as a five-day walkout by hospital resident doctors began over pay, led by the British Medical Association union. NHS chiefs said the health service was still 'open for business'. But ambulance crews and other NHS staff in the GMB union yesterday voted 67 per cent in favour of rejecting their 3.6 per cent offer for this year's pay rise. Paramedics joined nursing strikes in the winter of 2022-23 and could vote to do so again if they cannot get a better offer from Health Secretary Wes Streeting. National Secretary Rachel Harrison said: 'We have written to Wes Streeting, asking him to meet with us to discuss pay and other issues.' The Royal College of Nursing is also angry at getting a lower wage rise than doctors — and hospital consultants with the BMA are also considering striking again. As resident doctors, formerly called junior doctors, kicked off their strike to demand for a 29 per cent pay rise over the 5.4 per cent offer, Mr Streeting warned he could not guarantee patient safety. He said: 'I'm really proud of the way that NHS leaders and frontline staff have mobilised to minimise the disruption and the risk of harm to patients. 'What I can't do is guarantee there will be none. That's why the BMA's action is so irresponsible.' The BMA has made one exception for its strike so far. It allowed resident doctors to be called in to cover neo-natal intensive care at Nottingham City Hospital to protect newborn babies' lives. Strike leader Dr Melissa Ryan, who works there, said: 'We don't have enough senior staff to cover the doctors that aren't there. "It is important to us that those very sick babies get a lot of care.'